Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Life Sciences|May 7, 2021
Possible contribution of hepatocyte secretion to the elevation of plasma exosomal arginase-1 in high-fat diet-fed miceNoriyoshi Ogino, Hidekazu Takahashi, Kenjiro Nagaoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 23, 2019
Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver diseaseYuichi Honma, Michihiko Shibata, Tsuguru Hayashi, et al.
Internal Medicine (Tokyo, Japan)|January 18, 2021
Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of AtezolizumabYuichi Honma, Michihiko Shibata, Tomonori Gohda, et al.
Medical Molecular Morphology|July 2, 2020
Type 4B hereditary hemochromatosis due to heterozygous p.D157A mutation in SLC40A1 complicated with hypopituitarismYuichi Honma, Tsukasa Karasuyama, Keiichiro Kumamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 17, 2023
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter studyTomoya Sano, Keisuke Amano, Tatsuya Ide, et al.
Plos One|September 30, 2016
Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1Tatsuya Ide, Yuichiro Eguchi, Masaru Harada, et al.
Hepatology International|March 2, 2019
Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter studyTatsuya Ide, Hironori Koga, Masahito Nakano, et al.
Cancer Medicine|March 23, 2019
Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort studyMasahito Nakano, Hironori Koga, Tatsuya Ide, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2025
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinomaTetsu Tomonari, Shigeo Shimose, Issei Saeki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 21, 2025
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter StudyTakeshi Hatanaka, Shigeo Shimose, Takanori Ito, et al.
Pageof 7